Impedimed Limited · ASX:IPD
Impedimed — 2015 Bioshares Biotech Summit - Mike Hirshorn Address
19 slides from Impedimed's conference presentation, Jul 17, 2015
Slide 1: Mike Hirshorn Address
For personal use only Mike Hirshorn Address Presented by Rick Carreon Managing Director and CEO ImpediMed July 2015
Slide 2: Disclaimer
Disclaimer For personal use only The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. The information is provided in a summary form, does not purport to be complete and sh
Slide 3: Session Topic
Session Topic For personal use only This talk will cover the lessons being learned in commercialising L-Dex®diagnostic tool used in early detection and prevention of lymphoedema Issues or experiences that could be explored in this session include: What is the target market for ImpediMed, and how has
Slide 4: Our Journey
Our Journey For personal use only ® Nov 2013 CPT Category III to a Category I Code 1 year early Effective Jan 2015 Breast Cancer Related Lymphoedema to 2 years early Sept 2014 All Cancer Related Lymphoedema FT NCCN Guidelines RA 1 year early Apr 2015 D
Slide 5: Reimbursement
For personal use only Re imb urs me e nt
Slide 6: Does Cat I reimbursement guarantee success for medical device companies in the US?
Does Cat I reimbursement guarantee success for medical device companies in the US? For personal use only Competition Manufacturing NO! Quality Intellectual Property FDA Connectivity CMS Regulatory Reimbursement There is always risk with the commercialisation phase of any medical device
Slide 7: Let's stick with a Cat I for a moment
Let’s stick with a Cat I for a moment… 10 = 8 For personal use only 10 Medicare Jurisdictions that are managed by 8 Medicare Administrative Contractors 8 decisions impact 10 jurisdictions These decisions can change at any time for a number of reasons CPT I Code allows a physician to “seek reimbursem
Slide 8: Health Insurance Companies registered in the US
835 Health Insurance Companies registered in the US For personal use only 835 Decisions… Maybe And the reimbursement landscape is becoming even more volatile 4+5=2 ﹜ #4 #5 #2 For how long?
Slide 9: The Evolving US Healthcare System
The Evolving US Healthcare System Mergers and Acquisitions For personal use only Insurance Companies Medicare Administrative Contractors Hospitals Physician Practices Payment Schedules Transitioning from fee-for-service to value-based medicine
Slide 10: Clinical Evidence Secures Your Future
Clinical Evidence Secures Your Future For personal use only Level of Evidence Table Level Type of evidence (based on AHCPR 1992) Ia Evidence obtained from meta-analysis of randomized controlled trials Ib Evidence obtained from at least one randomized controlled trial IIa Evidence obtained from at le
Slide 11: Clinical Evidence Secures Your Future
Clinical Evidence Secures Your Future For personal use only Level 1b trial n=1100
Slide 12: What is the target market for ImpediMed, and how has this been ascertained?
What is the target market for ImpediMed, and how has this been ascertained? For personal use only How important is it to reassess a company’s corporate and marketing strategy and how has ImpediMed done this? What is the benefit of adopting trial sites and what is being learnt from these trial sites?
Slide 13: Technology Adoption Curve
Technology Adoption Curve For personal use only Growth Market Mainstream Market Crossing the Chasm Market Development Phase Late Market Early Market Innovators Early Adopters Early Majority Late Majority Laggards
Slide 14: Market Development Roadmap
Market Development Roadmap For personal use only MARKETING • Expanded Indication(s) material • Expand Promotional Activities • New Customer Targets • Referral Focus Foundational Requirements • Patient Advocacy Expansion MARKETING • Expand Social Media • Confirm Target Markets • Patient Outreach • St
Slide 15: Year Value of Acquired Customers
5 Year Value of Acquired Customers - Example - For personal use only Critical Questions Scalability? Reference Sites Long-term growth? High Potential Customers Who not to call on? Early Adopters Innovators Threshold
Slide 16: Customer Strategy
Customer Strategy Reference Sites For personal use only Tier III Targets NCCN Member Institutions Multidisciplinary Centres conducting 300 Designated Team - 499 more new breast cancer cases per year • NAPBC, NCI centres, ACO • Follow NCCN Guidelines Tier IV Targets Tier I Targets Multidisciplinary C
Slide 17: Targeted Launch
Targeted Launch For personal use only Prior 1 Yearto Breast Cancer Related Breast Surgeon Sept 2014 Early Lymphoedema 2 After Years All Cancer Related Oncology Sept 2014 Early Lymphoedema Centres 1 Year NCCN Multidisciplinary FT April 2015 Integrated RA Early Guidelines D Systems
Slide 18: Take Nothing for Granted (Part 2)
Take Nothing for granted (Part 2) For personal use only • The day you obtain your CPT I Code is the day you begin to defend it (carryover from last year) • High level clinical evidence secures your future (high number of patients at recognised institutions) • Your early adopters may not be your ulti
Slide 19: Thank You
For personal use only Thank You
ImpediMed — 2015 Bioshares Biotech Summit - Mike Hirshorn Address on 6ix